V‐domain immunoglobulin suppressor of T‐cell activation and programmed death receptor 1 dual checkpoint blockade enhances antitumour immunity and survival in glioblastoma
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.17404 ↗At a glance
Journal article in British Journal of Pharmacology, 2025. Written by Shasha Jin and 10 co-authors. Institution: New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. Major MEDLINE topics: Glioblastoma, Programmed Cell Death 1 Receptor, Brain Neoplasms, Immune Checkpoint Inhibitors. Cited 4 times so far (Crossref); 54 references. Funded by: Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (original language)
Background and Purpose The current therapy cannot meet the needs of glioblastoma (GBM). V‐domain immunoglobulin suppressor of T‐cell activation (VISTA) is significantly up‐regulated in GBM patients; however, its therapeutic potential in GBM is still unclear. Experimental Approach Flow cytometry was used to detect the expression of VISTA and the co‐expression pattern of VISTA and programmed death receptor 1 (PD‐1) on brain infiltrating lymphocytes of GBM mice. Monoclonal antibody therapy was used to evaluate the therapeutic effect of α ‐VISTA monotherapy and α ‐VISTA combined with α ‐PD‐1 on GBM mice. Transcriptome analysis, flow cytometry, and immunofluorescence were used to detect changes of immune microenvironment in mouse brain tumours. Immunofluorescence and TCGA data analysis were used to further validate the combined treatment strategy on patient data. Key Results Compared with normal mice, the frequency of VISTA expression and co‐expression of VISTA and PD‐1 on tumour‐infiltrating lymphocytes (TILs) in tumour‐bearing mice was increased. Anti‐VISTA monotherapy significantly up‐regulated multiple immune stimulation‐related pathways and moderately prolonged mouse survival time. Blocking the immune checkpoint VISTA and PD‐1 significantly prolonged the survival time of mice and cured about 80% of the mice; CD8 + T cells played an important role in this process. In addition, we found that the expression of VISTA and PD‐1 was significantly up‐regulated in GBM patients by immunofluorescence, and patients with high expression of VISTA and PD‐1 were associated with poor overall survival. This combination of blocking the immune checkpoint VISTA and PD‐1 may achieve clinical transformation in GBM.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
ORCID profiles: Shasha Jin
Funding
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Cite
APA
Jin, S., Li, T., Liu, L., Gao, T., Zhang, T., Yuan, D., Di, J., Guo, Z., Luo, Z., Yuan, H., & Liu, J. (2025). V‐domain immunoglobulin suppressor of T‐cell activation and programmed death receptor 1 dual checkpoint blockade enhances antitumour immunity and survival in glioblastoma. British Journal of Pharmacology. https://doi.org/10.1111/bph.17404
Vancouver
Jin S, Li T, Liu L, Gao T, Zhang T, Yuan D, et al. V‐domain immunoglobulin suppressor of T‐cell activation and programmed death receptor 1 dual checkpoint blockade enhances antitumour immunity and survival in glioblastoma. British Journal of Pharmacology. 2025. doi:10.1111/bph.17404
BibTeX
@article{Jin2025,
author = {Jin, Shasha and Li, Tao and Liu, Liu and Gao, Ting and Zhang, Tingting and Yuan, Dingyi and Di, Jianwen and Guo, Zhanying and Luo, Zhijie and Yuan, Haoliang and Liu, Jun},
title = {V‐domain immunoglobulin suppressor of T‐cell activation and programmed death receptor 1 dual checkpoint blockade enhances antitumour immunity and survival in glioblastoma},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.17404}
}
EUVIMED